MYNDF News and Press, MYND Life Sciences From 03/09/22

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2022) - MYND Life Sciences Inc.  (CSE: MYND) (OTCQB: MYNDF)   ("MYND" or "the Company") announces the hiring of a Senior Operations and Research Manager and the resignation of a company officer. MYND is pleased to announce the...

MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial PR Newswire Clinical validation of MYND Diagnostics' proprietary biomarkers in evaluating the efficacy of psilocybin-assisted psychothera...

One of the more mysterious and incurable diseases facing doctors looking for a treatment or a preventative drug is Alzheimer’s disease (AD), named after the German physician who identified the disease in the early part of the last century. According to the...

MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia Canada NewsWire MYND's Second CRA focuses on Novel Therapies for Neurological Diseases of the Brain VANCOUVER, BC , Jan. 12, 2022 /CNW/ - MYND Life Sci...

MYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer's Disease and other Dementias Canada NewsWire Acquisition will strengthen MYND's psilocybin-assisted medicinal and diagnostics capabilities, adding novel psychedelics for the treatment of...

MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application Canada NewsWire VANCOUVER, BC , Dec. 15, 2021 /CNW/ - MYND Life Sciences Inc. (" MYND " or the " Company ") (CSE: MYND) (OTC: MYNDF) is pleased to announc...

MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation PR Newswire R&D project on psilocybin's benefits in treating diseases of the brain VANCOUVER, BC , Nov. 30, 2021 /PRNewswire/ - MYND Life Sciences Inc. (" MYND "...

MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test Canada NewsWire MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics VANCOUVER, BC ,...

MYND Diagnostics Commences Clinical Research on Alzheimer's Disease Canada NewsWire The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer's Disease diagnostics VANCOUVER, BC , Nov. 16...

MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist Canada NewsWire Focused on generating data through proprietary biomarkers and diagnostic testing of inflammation VANCOUVER, BC , Nov. 9, 2021 /CNW/ - MYND LIFE SCIENCES...